You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 167 No. 4, February 26, 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (21)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Obesity
 •Pulmonary Diseases, Other
 •Diagnosis
 •Prognosis/ Outcomes
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Effect of Body Mass Index on Diagnostic and Prognostic Usefulness of Amino-Terminal Pro–Brain Natriuretic Peptide in Patients With Acute Dyspnea

Antoni Bayes-Genis, MD, PhD; Donald M. Lloyd-Jones, MD, ScM; Roland R. J. van Kimmenade, MD; John G. Lainchbury, MD; A. Mark Richards, MD, PhD; Jordi Ordoñez-Llanos, MD, PhD; Miquel Santaló, MD, PhD; Yigal M. Pinto, MD, PhD; James L. Januzzi Jr, MD

Arch Intern Med. 2007;167(4):400-407.

Background  Amino (N)–terminal pro–brain natriuretic peptide (NT-proBNP) testing is useful for diagnostic and prognostic evaluation in patients with dyspnea. An inverse relationship between body mass index (BMI); (calculated as weight in kilograms divided by height in meters squared) and NT-proBNP concentrations has been described.

Methods  One thousand one hundred three patients presenting to the emergency department with acute dyspnea underwent analysis. Patients were classified into the following 3 BMI categories: lean (<25.0), overweight (25.0-29.9), and obese (≥30.0).

Results  The NT-proBNP concentrations in the overweight and obese groups were significantly lower than in the lean patients, regardless of the presence of acute heart failure (P<.001). The positive likelihood ratio for an NT-proBNP–based diagnosis of acute heart failure was 5.3 for a BMI lower than 25.0, 13.3 for a BMI of 25.0 to 29.9, and 7.5 for a BMI of 30.0 or higher. A cut point of 300 ng/L had very low negative likelihood ratios in all 3 BMI categories (0.02, 0.03, and 0.08, respectively). Among decedents, the NT-proBNP concentrations were lower in the overweight and obese patients compared with the lean subjects (P<.001). Nonetheless, a single cut point of 986 ng/L strongly predicted 1-year mortality across the 3 BMI strata, regardless of the presence of acute heart failure (hazard ratios, 2.22, 3.06, and 3.69 for BMIs of <25.0, 25.0-29.9, and ≥30.0, respectively; all P<.004); the risk associated with a high NT-proBNP concentration was detected early and was sustained to a year after baseline in all 3 BMI strata (all P<.001).

Conclusions  In patients with and without acute heart failure, the NT-proBNP concentrations are relatively lower in overweight and obese patients with acute dyspnea. Despite this, the NT-proBNP concentration retains its diagnostic and prognostic capacity across all BMI categories.


Author Affiliations: Departments of Cardiology (Dr Bayes-Genis), Biochemistry and Molecular Biology (Dr Ordoñez-Llanos), and Emergency Medicine (Dr Santaló), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma, Barcelona, Spain; Division of Cardiology, Department of Preventive Medicine and Bluhm Cardiovascular Institute, Northwestern University, Chicago, Ill (Dr Lloyd-Jones); Department of Cardiology, University Hospital Maastricht, Maastricht, the Netherlands (Drs van Kimmenade and Pinto); Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Science, Christchurch, New Zealand (Drs Lainchbury and Richards); and Department of Cardiology, Massachusetts General Hospital, Boston (Dr Januzzi).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The obesity paradox in stable chronic heart failure does not persist after matching for indicators of disease severity and confounders
Frankenstein et al.
Eur J Heart Fail 2009;0:hfp150v1-hfp150.
ABSTRACT | FULL TEXT  

Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status
Frankenstein et al.
Eur Heart J 2008;29:2634-2640.
ABSTRACT | FULL TEXT  

State of the art: Using natriuretic peptide levels in clinical practice
Maisel et al.
Eur J Heart Fail 2008;10:824-839.
ABSTRACT | FULL TEXT  

Aminoterminal pro-brain natriuretic peptide (NT-proBNP) and sleep-disordered breathing in morbidly obese females: a cross-sectional study
Ybarra et al.
Diabetes and Vascular Disease Research 2008;5:19-24.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.